TD Asset Management Inc Invests $1.04 Million in ADMA Biologics Inc $ADMA

Key Points

• TD Asset Management Inc has invested approximately $1.04 million in ADMA Biologics, acquiring 56,852 shares during the 2nd quarter.
• ADMA Biologics reported $0.15 earnings per share (EPS) for the latest quarter, exceeding estimates, and has a revenue increase of 13.8% year-over-year.
• Analysts have set an average target price of $27.67 for ADMA Biologics, with the stock receiving multiple buy ratings from investment analysts.

TD Asset Management Inc bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 56,852 shares of the biotechnology company's stock, valued at approximately $1,035,000.

A number of other institutional investors have also made changes to their positions in ADMA. Intech Investment Management LLC increased its stake in shares of ADMA Biologics by 164.2% in the 1st quarter. Intech Investment Management LLC now owns 292,595 shares of the biotechnology company's stock valued at $5,805,000 after buying an additional 181,839 shares during the period. Strs Ohio acquired a new stake in shares of ADMA Biologics in the 1st quarter valued at $1,307,000. New York State Teachers Retirement System increased its stake in shares of ADMA Biologics by 96.2% in the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock valued at $4,402,000 after buying an additional 108,800 shares during the period. Vident Advisory LLC acquired a new stake in shares of ADMA Biologics in the 1st quarter valued at $2,735,000. Finally, Caxton Associates LLP acquired a new stake in shares of ADMA Biologics in the 1st quarter valued at $668,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $15.16 on Thursday. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The stock's 50 day moving average price is $15.88 and its 200-day moving average price is $18.29. The company has a market capitalization of $3.62 billion, a PE ratio of 17.63 and a beta of 0.47. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business's revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 earnings per share. On average, equities analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "buy (b-)" rating on shares of ADMA Biologics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.